About Us

Targeted Cancer Therapeutics

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells
without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel
product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.

Novel Approach and Technology

  • Proprietary discovery and development expertise
  • Cationic lytic peptide (CLYPTM) technology platform
    • Targeted Membrane disrupting peptides (MDPs)
    • Antibody drug conjugates (ADCs)